n p-mTOr p-Akt p-4BEP1 p-PTEN     positive P positive P positive P positive P Tumortyp                   Typ1 24 22 (91.7) 0.082 17 (70.8) 0.438 24 (100) 0.001 24 (100) 0.092 Typ2 3 3 (100)   2 (66.7)   3 (100)   3 (100)   Typ3 4 2 (50)   3 (75)   2 (50)   2 (50)   Typ4 4 3 (75)   1 (25)   3 (75)   3 (75)   Ki67                   <=2 21 21 (100) 0.032 15 (71.4) 0.423 20 (95.2) 0.242 21(100) 0.004 2-20 11 8 (72.7)   7 (63.6)   9 (81.8)   11(100)   >=20 3 2 (66.7)   1 (33.3)   2 (66.7)   2 (66.7)   Metastasis                   yes 9 7 (77.7) 0.238 4 (44.4) 0.119 6 (66.7) 0.017 8 (88.9) 0.085 no 26 24 (92.3)   19 (73.1)   25(96.1)   26(100)   ENETS                   Stage 0 15 14 (93.3) 0.119 12 (78.5) 0.222 15(100) 0.002 15(100) 0.186 Stage 1 10 10 (100)   5 (50)   10(100)   10(100)   Stage 2 3 2 (66.6)   3 (100)   2 (66.7)   3 (100)   Stage 3 2 2 (100)   1 (50)   2 (100)   2 (100)   Stage 4 5 3 (60)   2 (40)   2 (40)   4 (80)

Table 3: Relation between the expression of p-mTOR, pAkt, p4BEP1, pPTEN and clinico-pathological characteristics